Latest Eloxatin Stories

2010-04-29 07:00:00

PARIS, April 29 /PRNewswire-FirstCall/ -- Change on Change at a constant reported exchange Q1 2010 Q1 2009 basis rates ------- ------- --------- --------- EUR EUR Net sales 7,385m 7,107m...

2010-04-05 10:40:00

WOODCLIFF LAKE, N.J., April 5 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it (and its subsidiary Par Pharmaceutical and development partner MN Pharmaceuticals of Turkey) has entered into a settlement agreement with sanofi-aventis (sanofi) that resolves patent litigation related to its generic version of sanofi's and Debiopharm's Eloxatin(®) (oxaliplatin injection) product, a drug used to treat colorectal cancer, in the U.S....

2009-10-30 07:13:00

BRIDGEWATER, N.J., Oct. 30 /PRNewswire-FirstCall/ -- 2009 Q3 Change Change at 2009 Change Change at on a constant 9 months on a constant reported exchange reported exchange basis rates basis rates ------- -------- -------- -------- -------- --------- euro euro...

2009-08-05 07:00:00

BETHESDA, Md. and BRIDGEWATER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Today, the Foundation for the National Institutes of Health and sanofi-aventis announced an unprecedented donation by the global pharmaceutical leader providing approximately $1.3 million in pharmaceutical therapies for ongoing use in clinical trials and other therapeutic treatments at the National Institutes of Health (NIH) Clinical Center. Designated by the Foundation for NIH as the Clinical Center Drug Donation...

2009-06-18 18:19:00

-- Has Tentative FDA Approval and Expects Final Approval Shortly -- LAKE FOREST, Ill., June 18 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S. District Court for the District of New Jersey has granted summary judgment of non-infringement in Hospira's favor with regard to Sanofi Aventis' chemotherapy medication Eloxatin(R), and that Hospira has tentative approval from the U.S. Food and Drug...

2009-02-11 07:00:00

PARIS, Feb. 11 /PRNewswire-FirstCall/ -- FY 2008 % change Q4 2008 % change ------- -------- ------- -------- Comparable net sales*: EUR27,568m +3.7% EUR7,089m +3.6% Adjusted net income excluding selected items(1): EUR7,186m +3.2% EUR1,627m +13.9% Adjusted EPS excluding EUR5.49 +6.2% EUR1.25 +16.8% selected...

2007-01-23 15:00:58

Preliminary results show the combination of Xeloda plus Eloxatin, known as XELOX, to be equivalent to standard FOLFOX-4 chemotherapy treatment in terms of overall survival in first-line metastatic colorectal cancer patients. Given its dosing convenience advantage, XELOX has the potential to be a first-line treatment, provided it can be demonstrated as cost-effective. The 2,034 metastatic colorectal cancer patient study was originally designed to compare first-line XELOX (Roche/Chugai's...

2004-11-29 18:00:12

PARIS, Nov. 29 /PRNewswire-FirstCall/ -- Patients who received ELOXATIN-based chemotherapy (FOLFOX4) plus bevacizumab (Avastin(TM)) showed a statistically significant improvement in overall survival in a large randomized clinical study sponsored by the National Cancer Institute and conducted by the Eastern Cooperative Oncology Group (ECOG). Preliminary results announced today are showing a 26% reduction in the risk of death for patients receiving FOLFOX4 plus bevacizumab (Avastin(TM))...

Word of the Day
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'